Sep 26, 2019
Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
Jul 12, 2019
Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation
Jul 10, 2019
Revlimid (lenalidomide; Celgene) Drug Overview & Product Profiles 2017-2026: An Oral Thalidomide Analog with Antineoplastic, Immunomodulatory, and Anti-Angiogenic Properties
Jun 19, 2019
World Multiple Myeloma Disease Coverage Forecast and Market 2018-2024: Leading Multiple Myeloma Drugs will Soon Face Generic Competition
Jun 16, 2019
New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
May 29, 2019
DARZALEX® (daratumumab) Phase 3 MAIA Study Results, Published in The New England Journal of Medicine, Show Combination Therapy Increases Progression-Free Survival in Newly Diagnosed Patients with Multiple Myeloma Who are Transplant Ineligible
Apr 29, 2019
I-Mab Biopharma and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma
Mar 12, 2019
OncoTracker Expands Multiple Myeloma Intellectual Property
Feb 22, 2019
Roswell Park Presentations at TCT Meeting Focus on Tools for Predicting Patient Outcomes
Feb 12, 2019
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
Dec 01, 2018
DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
Nov 07, 2018
MDS Drugs Market Size Worth $2.4 Billion by 2022 | CAGR: 9.7%: Grand View Research, Inc.
Nov 01, 2018
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
Nov 01, 2018
Oncopeptides to Present Updated Data From the Two Ongoing Trials ANCHOR and HORIZON in Patients with RRMM at ASH in December 2018
Oct 31, 2018
In Multiple Myeloma, Janssen's Darzalex Posted Significant Gains Over the Past Six Months, but May Face an Increasingly Restrictive Payer Environment
Oct 11, 2018
MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
Aug 27, 2018
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Jun 15, 2018
European Hematology Association: Is RELEVANCE Relevant? Results of the Phase III Study of R2 vs R-chemo in First-line Follicular Lymphoma
Jun 07, 2018
Evolving Treatment Strategies in Multiple Myeloma: Janssen's Darzalex Leads a Host of Novel Agents in Redefining Treatment Strategies and Approaches
May 07, 2018
Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible